Get the Stockscreener App
1.105
8.33%
0.085
Pre-market:
1.08
-0.025
-2.26%
Inflarx N V stock is traded at $1.105, with a volume of 770.13K.
It is up +8.33% in the last 24 hours and down -12.99% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.02
Open:
$1
24h Volume:
770.13K
Relative Volume:
0.29
Market Cap:
$74.86M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.2786
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-7.14%
1M Performance:
-12.99%
6M Performance:
+30.00%
1Y Performance:
-53.38%
1-Day Range:
$0.99
$1.11
1-Week Range:
$0.9201
$1.28
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.105 | 69.10M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx (NASDAQ:IFRX) Stock Rating Lowered by Leerink Partnrs - Defense World
Will InflaRx N.V. stock outperform Nasdaq indexJuly 2025 Update & Community Supported Trade Ideas - Newser
Is InflaRx N.V. (IF0) stock testing key supportWeekly Market Report & Risk Controlled Swing Alerts - Newser
InflaRx (IFRX) Downgraded by Leerink Partners with Lowered Price Target | IFRX Stock News - GuruFocus
Leerink Partners downgrades Inflarx stock rating to Market Perform on financing concerns - Investing.com Nigeria
Leerink Partners Downgrades InflaRx to Market Perform From Outperform, Adjusts PT to $2 From $5 - marketscreener.com
InflaRx N.V. (IFRX) 5.6% in After-hours: What’s Driving the Move? - Stocks Telegraph
Will InflaRx N.V. (IF0) stock deliver compounding returns2025 Investor Takeaways & Capital Efficiency Focused Strategies - Newser
How InflaRx N.V. (IF0) stock moves in volatile trading sessions2025 Price Action Summary & Safe Entry Trade Reports - Newser
Is InflaRx N.V. (IF0) stock supported by strong fundamentalsStop Loss & Verified Short-Term Trading Plans - Newser
What margin trends mean for InflaRx N.V. stock2025 Market Outlook & AI Forecasted Entry/Exit Points - Newser
Inflarx flexes; HS, CSU continue to percolate - BioWorld MedTech
Ready to Jump After Recent Trade: InflaRx N.V (IFRX) - Setenews
Cash per share of InflaRx N.V. – BER:IF0 - TradingView
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can InflaRx N.V. (IF0) stock surprise with quarterly results2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
Will InflaRx N.V. stock deliver strong dividend growthGold Moves & AI Enhanced Trading Signals - newser.com
Is InflaRx N.V. stock attractive for income investorsEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Can InflaRx N.V. stock sustain market leadershipWeekly Trend Recap & AI Driven Price Predictions - newser.com
InflaRx N.V. stock prediction for this weekMarket Rally & AI Driven Price Predictions - newser.com
Is InflaRx N.V. (IF0) stock cheap vs fundamentalsJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
InflaRx Stock: Gohibic Flops, INF904 Underwhelms, Cash Burn Accelerates (NASDAQ:IFRX) - Seeking Alpha
Can InflaRx N.V. recover in the next quarter2025 Stock Rankings & Technical Pattern Based Signals - newser.com
Will InflaRx N.V. (IF0) stock maintain strong growthMarket Growth Review & Low Risk High Reward Ideas - newser.com
Why InflaRx N.V. stock is considered a top pickMarket Growth Summary & AI Driven Stock Price Forecasts - newser.com
Volatility clustering patterns for InflaRx N.V.Entry Point & Risk Managed Investment Signals - newser.com
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):